Safety and Efficacy of Long-Acting Injectable Cabotegravir as Preexposure Prophylaxis To Prevent HIV Acquisition

Interest in Injectable and Oral PrEP for HIV Prevention Among Women and Men Who Inject Drugs

This article from Journal of Addiction Medicine examines interests and concerns around use of oral and injectable PrEP amongst people who inject drugs in the United States.

PrEP Booklet of Frequently Asked Questions (FAQs): A Peer Outreach Worker Tool

This tool was developed to be used by peer outreach workers, peer educators, and other community-based health providers to help provide comprehensive information about pre-exposure prophylaxis (PrEP) to key population peers.

Long-Acting PrEP for Key Populations: Considerations for Implementation

This document is intended for program implementers, advocates, policymakers, and other stakeholders who influence the rollout of long-acting options for pre-exposure prophylaxis (PrEP). It highlights some of the considerations for long-acting PrEP implementation for key population individuals.

Understanding the Drivers of CAB PrEP Uptake and Use among Women in sub-Saharan Africa to Build Demand for New PrEP Methods

This article from Current HIV/AIDS Reports reviews facilitators and barriers to use of injectable cabotegravir (CAB) for PrEP by women in sub-Saharan Africa.

Global Acute HIV Infection Algorithm Job Aids for Providers

This tool can assist providers in assessing acute HIV infection (AHI) in clients using oral PrEP, PrEP ring, and CAB PrEP by offering guidance through three steps: HIV testing, recent exposure to HIV assessment, and AHI assessment. Providers are encouraged to use clinical judgement and defer to national guidance as needed.

Daily Oral PrEP, PrEP Ring, and CAB PrEP Template Guidelines (Spanish)

The intent of this document is to provide adaptable guidelines to support the development and adoption of national guidelines that align with World Health Organization (WHO) pre-exposure prophylaxis (PrEP) recommendations and guidance, including those for tenofovir disoproxil fumarate (TDF)-based oral PrEP, the monthly dapivirine vaginal ring (“PrEP ring” or “the ring”), and injectable cabotegravir (CAB…

HIV Prevention User Journey Tool

The HIV Prevention Journey Tool was developed to support adolescent girls and young women to explore methods that would align with their lifestyle, needs and personal preferences; and support healthcare providers to provide informed counseling based on client needs. The digital tool, which has been optimized for use on mobile devices, can be accessed here.…

2024 Q3 Global PrEP Tracker

AVAC’s Global PrEP Tracker offers two views on PrEP uptake around the world. Visit data.prepwatch.org for a dynamic map-based tool to explore trends in oral PrEP use globally as countries introduce and scale up PrEP programs. For insights on the full scope of PrEP use around the world, the PrEP Tracker as a spreadsheet offers…

Oral PrEP, PrEP Ring, and CAB PrEP Template Guidelines (English)

The intent of this document is to provide adaptable guidelines to support the development and adoption of national guidelines that align with World Health Organization (WHO) pre-exposure prophylaxis (PrEP) recommendations and guidance, including those for tenofovir disoproxil fumarate (TDF)-based oral PrEP, the monthly dapivirine vaginal ring (“PrEP ring” or “the ring”), and injectable cabotegravir (CAB…

Implementation Plan for the Introduction of the PrEP Ring and Long-acting Injectable Cabotegravir for HIV Prevention – Eswatini, August 2024